Works about INTERLEUKIN-23

Results: 468
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS).

    Published in:
    Journal of Clinical Medicine, 2024, v. 13, n. 2, p. 495, doi. 10.3390/jcm13020495
    By:
    • Gargiulo, Luigi;
    • Ibba, Luciano;
    • Malagoli, Piergiorgio;
    • Amoruso, Fabrizio;
    • Argenziano, Giuseppe;
    • Balato, Anna;
    • Bardazzi, Federico;
    • Burlando, Martina;
    • Carrera, Carlo Giovanni;
    • Damiani, Giovanni;
    • Dapavo, Paolo;
    • Dini, Valentina;
    • Franchi, Chiara;
    • Gaiani, Francesca Maria;
    • Girolomoni, Giampiero;
    • Guarneri, Claudio;
    • Lasagni, Claudia;
    • Loconsole, Francesco;
    • Marzano, Angelo Valerio;
    • Maurelli, Martina
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18

    Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells.

    Published in:
    Molecular Medicine Reports, 2020, v. 22, n. 1, p. 507, doi. 10.3892/mmr.2020.11128
    By:
    • Vázquez-Sánchez, Ernesto A.;
    • Mendoza-Figueroa, José S.;
    • Gutiérrez-Gonzalez, Guadalupe;
    • Zapi-Colín, Luis A.;
    • Torales-Cardeña, Azael;
    • Briseño-Lugo, Paola E.;
    • Díaz-toalá, Iván;
    • Cancino-Diaz, Juan C.;
    • Pérez-Tapia, Sonia M.;
    • Cancino-Diaz, Mario E.;
    • Gómez-Chávez, Fernando;
    • Rodríguez-Martínez, Sandra
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2025, v. 39, p. 7, doi. 10.1111/jdv.20187
    By:
    • Bonifati, C.;
    • Lembo, S.;
    • Richetta, A. G.;
    • Romanelli, M.;
    • Satolli, F.;
    • Corazza, M.;
    • Atzori, L.;
    • Lasagni, C.;
    • Potenza, C.;
    • Savoia, P.;
    • Bardazzi, F.;
    • Di Lernia, V. G.;
    • Bianchi, L.;
    • Fabbrocini, G.;
    • Giofrè, C.;
    • Zichichi, L.;
    • Guarneri, C.;
    • Pallotta, S.;
    • Fargnoli, M. C.;
    • Loconsole, F.
    Publication type:
    Article
    29

    Anti‐IL‐23 therapy for the treatment of moderate‐to‐severe inverse psoriasis: A 52‐week multicenter study.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2025, v. 39, n. 3, p. e290, doi. 10.1111/jdv.20346
    By:
    • Ceravalls, Joan;
    • Ruiz‐Villaverde, Ricardo;
    • Armesto, Susana;
    • Fernández‐Armenteros, Josep Manel;
    • Riera‐Monroig, Josep;
    • Gracia‐Cazaña, Tamara;
    • Quintana‐Codina, Mònica;
    • Iglesias‐Sancho, Maribel;
    • Salleras, Montserrat;
    • Moya, Adrián Imbernón;
    • Melgosa Ramos, Francisco Javier;
    • Ferran, Marta
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Risankizumab: Daily Practice Experience of High Need Patients.

    Published in:
    Biomedicines, 2023, v. 11, n. 6, p. 1769, doi. 10.3390/biomedicines11061769
    By:
    • Brunasso, Alexandra M. G.;
    • Burlando, Martina;
    • Amoruso, Fabrizio;
    • Arancio, Luisa;
    • Malara, Giovanna;
    • Manzo, Raffaella;
    • Montesu, Maria Antonia;
    • Caldarola, Giacomo
    Publication type:
    Article
    49
    50